Andrés Valentí

Dr. Andrés Valentí

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 August 2016 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
JLJosé María Lamo-Espinosa
José María Lamo-Espinosa
GMGonzalo Mora
Gonzalo Mora
JBJuan Francisco Blanco Blanco
Juan Francisco Blanco Blanco
FGFroilán Granero-Moltó
Froilán Granero-Moltó
JNJorge M. Núñez-Córdoba
Jorge M. Núñez-Córdoba
FPFelipe Prosper
Felipe Prosper
Mesenchymal stromal cells are a promising option to treat knee osteoarthritis. Their safety and usefulness must be confirmed and the optimal dose established. We tested increasing doses of bone marrow mesenchymal stromal cells (BM-MSCs) in combination with hyaluronic acid in a randomized clinical trial. A phase I/II multicenter randomized clinical trial with active control was conducted. Thirty patients diagnosed with knee OA were randomly assigned to intraarticularly administered hyaluronic acid alone (control), or together with 10 × 106 or 100 × 106 cultured autologous BM-MSCs, and followed up for 12 months. Pain and function were assessed using VAS and WOMAC and by measuring the knee motion range. X-ray and magnetic resonance imaging analyses were performed to analyze joint damage. No adverse effects were reported after BM-MSC administration or during follow-up. BM-MSC-administered patients improved according to VAS during all follow-up evaluations and median value (IQR) for control, low-dose and high-dose groups change from 5 (3, 7), 7 (5, 8) and 6 (4, 8) to 4 (3, 5), 2 (1, 3) and 2 (0,4) respectively at 12 months (low-dose vs control group p = 0.005 and high-dose vs control group p < 0.009). BM-MSC-administered patients were also superior according to WOMAC, although improvement in control and low-dose patients could not be significantly sustained beyond 6 months. On the other hand, the BM-MSC high-dose group exhibited an improvement of 16.5 (12, 19) points at 12 months (p < 0.01). Consistent with WOMAC and VAS values, motion ranges remained unaltered in the control group but improved at 12 months with BM-MSCs. X-ray revealed a reduction of the knee joint space width in the control group that was not seen in BM-MSCs high-dose group. MRI (WORMS protocol) showed that joint damage decreased only in the BM-MSC high-dose group, albeit slightly. The single intraarticular injection of in vitro expanded autologous BM-MSCs together with HA is a safe and feasible procedure that results in a clinical and functional improvement of knee OA, especially when 100 × 106 cells are administered. These results pave the way for a future phase III clinical trial. Clinical Trials.gov identifier NCT02123368. Nº EudraCT: 2009-017624-72

1 November 2009 in Arthroscopy
Verified
Journal Article
Closed access
JNJuan Ramón Valentí Nin
Juan Ramón Valentí Nin
GGGonzalo Mora Gasque
Gonzalo Mora Gasque
AVAndrés Valentí
Andrés Valentí
JBJesús Dámaso Aquerreta Beola
Jesús Dámaso Aquerreta Beola
MGMilagros Hernandez Gonzalez
Milagros Hernandez Gonzalez

14 July 2013 in MUSCULOSKELETAL SURGERY
Verified
Journal Article
Closed access
PDF file
LML. Muñoa
L. Muñoa
AGA. B. González
A. B. González
PRP. Díaz de Rada
P. Díaz de Rada
AVAndrés Valentí
Andrés Valentí
JVJ. R. Valentí
J. R. Valentí

7 March 2021 in Geriatrics
Verified
Journal Article
Open access
PDF file
JLJosé María Lamo-Espinosa
José María Lamo-Espinosa
JGJorge Gómez
Jorge Gómez
JGJavier Gatica
Javier Gatica
ÁSÁlvaro Suárez
Álvaro Suárez
VMVictoria Moreno
Victoria Moreno
JVJuan Ramón Valentí-Nin
Juan Ramón Valentí-Nin
Several studies have shown that double mobility (DM) cups reduce postoperative dislocations. Does the cemented dual mobility cup reduce dislocations in a specific cohort of elder patients with a high dislocation risk? Our hypothesis is that this implant is optimal for elder patients because it reduces early dislocation. We have retrospectively reviewed elder patients who underwent total hip arthroplasty (THA) with cemented double mobility cup between March 2009 and January 2018. The inclusion criteria were patients (>75 years) who were operated on for primary THA (osteoarthritis or necrosis) with a cemented dual mobility cup and a high-risk instability (at least two patient-dependent risk factors for instability). The exclusion criteria were revision surgeries or hip fracture. In all the cases, the same surgical approach was performed with a Watson Jones modified approach in supine position. We have collected demographic data, instability risk factors. Patients were classified using the Devane’s score, Merle d’Aubigné score and the patient’s likelihood of falling with the Morse Fall Scale. Surgical and follow-up complications were collected from their medical history. Sixty-eight arthroplasties (68 patients) were included in the study. The median age was 81.7 years (SD 6.4), and the American Society of Anesthesiologists (ASA) score showed a distribution: II 27.94%, III 63.24% and IV 8.82%. Devane’s score was less than five in all of the cases. At least two patient-dependent risk factors for instability (87% had three or more) were present in each case. The median follow-up time was 49.04 months (SD 22.6). Complications observed were two cases of infection and one case of aseptic loosening at 15 months which required revision surgery. We did not observe any prosthetic dislocation. The cemented dual mobility cup is an excellent surgical option on primary total hip arthroplasties for elder patients with high-risk instability.

1 January 2014 in Health and Quality of Life Outcomes
Verified
Journal Article
Open access
PDF file
ECEnric Castellet
Enric Castellet
OAOscar Ares
Oscar Ares
FCFernando Celaya
Fernando Celaya
AVAndrés Valentí
Andrés Valentí
ASAngels Salvador
Angels Salvador
(G(SEROD group)
(SEROD group)
The purpose of the present study is to translate and validate the “Hip and Knee Outcomes Questionnaire”, developed in English, into Spanish. The ‘Hip and Knee Outcomes Questionnaire is a questionnaire planned to evaluate the impact in quality of life of any problem related to the human musculoskeletal system. 10 scientific associations developed it.

1 October 2020 in The Knee
Verified
Journal Article
Closed access
LMLara Gil Melgosa
Lara Gil Melgosa
AVAndrés Valentí
Andrés Valentí
ÁSÁlvaro Suárez
Álvaro Suárez
VMVerónica Montiel
Verónica Montiel